DK2970948T3 - METHODS OF RNA PURIFICATION - Google Patents
METHODS OF RNA PURIFICATION Download PDFInfo
- Publication number
- DK2970948T3 DK2970948T3 DK14709704.2T DK14709704T DK2970948T3 DK 2970948 T3 DK2970948 T3 DK 2970948T3 DK 14709704 T DK14709704 T DK 14709704T DK 2970948 T3 DK2970948 T3 DK 2970948T3
- Authority
- DK
- Denmark
- Prior art keywords
- rna
- sample
- buffer
- purification
- chromatography
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3847—Multimodal interactions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1017—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D2015/3838—Ligand exchange chromatography, e.g. complexation chromatography, chelation chromatography, metal interaction chromatography
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361799705P | 2013-03-15 | 2013-03-15 | |
| PCT/EP2014/055014 WO2014140211A1 (fr) | 2013-03-15 | 2014-03-13 | Procédés de purification de l'arn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2970948T3 true DK2970948T3 (en) | 2019-04-08 |
Family
ID=50272650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14709704.2T DK2970948T3 (en) | 2013-03-15 | 2014-03-13 | METHODS OF RNA PURIFICATION |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11155572B2 (fr) |
| EP (2) | EP3521429B1 (fr) |
| JP (1) | JP6461830B2 (fr) |
| CN (1) | CN105283548A (fr) |
| BR (1) | BR112015023513A2 (fr) |
| CA (1) | CA2906281A1 (fr) |
| CY (1) | CY1121478T1 (fr) |
| DK (1) | DK2970948T3 (fr) |
| ES (2) | ES2923018T3 (fr) |
| HR (1) | HRP20190197T1 (fr) |
| HU (1) | HUE042072T2 (fr) |
| LT (1) | LT2970948T (fr) |
| PL (1) | PL2970948T3 (fr) |
| PT (1) | PT2970948T (fr) |
| SI (1) | SI2970948T1 (fr) |
| TR (1) | TR201903248T4 (fr) |
| WO (1) | WO2014140211A1 (fr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EA201591229A1 (ru) * | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
| LT2970948T (lt) * | 2013-03-15 | 2019-03-25 | Glaxosmithkline Biologicals Sa | Rna gryninimo būdai |
| WO2014152031A1 (fr) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Purification d'acide ribonucléique |
| WO2015048744A2 (fr) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucléotides codant des polypeptides de modulation immunitaire |
| CA2926218A1 (fr) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides codant pour un recepteur de lipoproteines de faible densite |
| BR112016024644A2 (pt) | 2014-04-23 | 2017-10-10 | Modernatx Inc | vacinas de ácido nucleico |
| EA201691696A1 (ru) | 2014-04-25 | 2017-03-31 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
| WO2016180430A1 (fr) | 2015-05-08 | 2016-11-17 | Curevac Ag | Procédé de production d'arn |
| WO2016193206A1 (fr) | 2015-05-29 | 2016-12-08 | Curevac Ag | Procédé de production et de purification d'arn, comprenant au moins une étape de filtration à flux tangentiel |
| EP3699288A1 (fr) | 2015-08-07 | 2020-08-26 | CureVac AG | Procédé pour la production in vivo d'arn dans une cellule hôte |
| US11162880B2 (en) | 2015-11-09 | 2021-11-02 | University Of Notre Dame Du Lac | Particle size purification method and devices |
| JP2019500043A (ja) | 2015-12-28 | 2019-01-10 | ノバルティス アーゲー | 異常ヘモグロビン症の治療用組成物および方法 |
| JP7153009B2 (ja) * | 2016-07-21 | 2022-10-13 | スパーク セラピューティクス インコーポレイテッド | 高収率の組換えアデノ随伴ウイルス（ｒＡＡＶ）ベクターを生成するための、規模拡大可能な高回収率の方法、及びそれにより生成される組換えアデノ随伴ウイルス（ｒＡＡＶ）ベクター |
| WO2018041921A1 (fr) | 2016-08-31 | 2018-03-08 | Curevac Ag | Dispositif de mélange pour la production d'une composition d'acide nucléique liquide |
| CN116837052A (zh) | 2016-09-14 | 2023-10-03 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
| WO2018096179A1 (fr) | 2016-11-28 | 2018-05-31 | Curevac Ag | Procédé de purification d'arn |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
| EP3971291A1 (fr) | 2017-02-27 | 2022-03-23 | Translate Bio, Inc. | Procédés de purification d'arn messager |
| WO2018211038A1 (fr) | 2017-05-17 | 2018-11-22 | Curevac Ag | Procédé de détermination d'au moins un paramètre de qualité d'un échantillon d'arn |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| WO2019030718A1 (fr) | 2017-08-11 | 2019-02-14 | Glaxosmithkline Biologicals Sa | Procédé d'identification d'arn utilisant la digestion par rnase h et le fractionnement de taille |
| EP3668977A4 (fr) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | Procédés analytiques par hplc |
| EP3668979A4 (fr) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | Procédés pour analyse par clhp |
| WO2019046809A1 (fr) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | Procédés de fabrication de nanoparticules lipidiques |
| US11325104B2 (en) * | 2017-12-07 | 2022-05-10 | Emp Biotech Gmbh | System and method of applied radial technology chromatography |
| RU2765877C1 (ru) * | 2018-06-28 | 2022-02-04 | Кьюрвак Аг | Биореактор для транскрипции рнк in vitro |
| CA3108544A1 (fr) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Procedes de purification d'arn messager |
| AU2019365382B2 (en) * | 2018-10-24 | 2024-02-08 | F. Hoffmann-La Roche Ag | Process for the purification of oligonucleotides |
| US20220098574A1 (en) * | 2019-01-29 | 2022-03-31 | Flagship Pioneering Innovations V, Inc. | Methods of separating long polynucleotides from a composition |
| EP3924487B1 (fr) * | 2019-02-11 | 2024-04-10 | ethris GmbH | Purification d'arnm par filtration tangentielle |
| WO2020257275A1 (fr) * | 2019-06-20 | 2020-12-24 | Arcturus Therapeutics, Inc. | Plate-forme de purification de transcription in vitro améliorée |
| WO2021123920A1 (fr) | 2019-12-18 | 2021-06-24 | Novartis Ag | Compositions et méthodes pour le traitement d'hémoglobinopathies |
| US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
| WO2021168306A1 (fr) * | 2020-02-21 | 2021-08-26 | Biogen Ma Inc. | Procédés de préparation de compositions oligonucléotidiques à l'aide d'une ultrafiltration/diafiltration |
| WO2021229217A1 (fr) * | 2020-05-12 | 2021-11-18 | Cranfield University | Procédé et appareil modulaire pour la synthèse d'agents thérapeutiques à base d'arn |
| CN111812230A (zh) * | 2020-06-24 | 2020-10-23 | 南京济群生物科技有限公司 | 一种半定量测定dna中rna含量的sec-hplc检测方法 |
| US11345723B2 (en) * | 2020-09-14 | 2022-05-31 | Mobius Biomedical, Inc. | Process technology for biological product manufacturing and downstream purification |
| WO2022240960A1 (fr) * | 2021-05-14 | 2022-11-17 | Crispr Therapeutics Ag | Synthèse et purification à grande échelle d'arnm |
| WO2022266389A1 (fr) * | 2021-06-17 | 2022-12-22 | Modernatx, Inc. | Stratégies alternatives de purification d'arn |
| EP4359527A2 (fr) | 2021-06-23 | 2024-05-01 | Novartis AG | Compositions et méthodes pour le traitement d'hémoglobinopathies |
| WO2023031858A1 (fr) | 2021-09-01 | 2023-03-09 | Glaxosmithkline Biologicals Sa | Procédés de purification d'adn plasmidique |
| WO2023073228A1 (fr) | 2021-10-29 | 2023-05-04 | CureVac SE | Arn circulaire amélioré pour exprimer des protéines thérapeutiques |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256294A (en) | 1990-09-17 | 1993-10-26 | Genentech, Inc. | Tangential flow filtration process and apparatus |
| US6011148A (en) | 1996-08-01 | 2000-01-04 | Megabios Corporation | Methods for purifying nucleic acids |
| EP0853123A1 (fr) | 1997-01-10 | 1998-07-15 | Roche Diagnostics GmbH | Purification d'ADN à l'aide de 'cross-flow-filtration' |
| WO1999040098A1 (fr) * | 1998-02-04 | 1999-08-12 | Merck Patent Gmbh | Procede pour isoler et purifier des acides nucleiques |
| CA2457565A1 (fr) * | 2001-10-09 | 2003-04-17 | Genentech, Inc. | Nouvelles proteines mammaliennes acides et acides nucleiques les codant |
| US8075780B2 (en) | 2003-11-24 | 2011-12-13 | Millipore Corporation | Purification and concentration of synthetic biological molecules |
| US20050266550A1 (en) | 2004-05-18 | 2005-12-01 | Alphavax, Inc. | TC-83-derived alphavirus vectors, particles and methods |
| WO2008073620A2 (fr) * | 2006-11-02 | 2008-06-19 | Neose Technologies, Inc. | Procédé de fabrication pour la production de polypeptides exprimés dans des lignées cellulaires d'insectes |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| EP2451475A2 (fr) | 2009-07-06 | 2012-05-16 | Novartis AG | Molécules d'arn autorépliquantes et leurs utilisations |
| WO2012006369A2 (fr) | 2010-07-06 | 2012-01-12 | Novartis Ag | Immunisation de grands mammifères à l'aide de faibles doses d'arn |
| MX343410B (es) | 2010-07-06 | 2016-11-04 | Novartis Ag * | Emulsiones cationicas de agua en aceite. |
| CA2804494A1 (fr) | 2010-07-06 | 2012-01-12 | Novartis Ag | Particules d'administration de type virion pour des molecules d'arn auto-repliquant |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| EP2593546A4 (fr) * | 2010-07-16 | 2014-01-01 | Valorisation Recherche Ltd Partnership | Purification par affinité d'arn dans des conditions d'origine sur la base de l'interaction lambda boîteb/n peptide |
| ES2727583T3 (es) | 2010-08-31 | 2019-10-17 | Glaxosmithkline Biologicals Sa | Lípidos adecuados para la administración liposómica de ARN que codifica proteínas |
| LT3981427T (lt) | 2010-08-31 | 2022-08-10 | Glaxosmithkline Biologicals S.A. | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| HRP20221048T1 (hr) | 2010-08-31 | 2022-11-11 | Glaxosmithkline Biologicals Sa | Mali liposomi za isporuku rna koja kodira imunogen |
| JP2014506873A (ja) | 2010-12-10 | 2014-03-20 | トンプソン トレイシー | 分離方法のための組成物 |
| WO2013006837A1 (fr) | 2011-07-06 | 2013-01-10 | Novartis Ag | Emulsions huile dans eau cationiques |
| EP2729126B1 (fr) | 2011-07-06 | 2020-12-23 | GlaxoSmithKline Biologicals SA | Liposomes ayant un rapport n:p utile pour délivrance de molécules d'arn |
| EP3424495A1 (fr) | 2011-07-06 | 2019-01-09 | GlaxoSmithKline Biologicals S.A. | Émulsions aqueuses contenant des acides nucléiques |
| CA2840989A1 (fr) | 2011-07-06 | 2013-01-10 | Novartis Ag | Compositions de combinaisons immunogenes et utilisations de celles-ci |
| DE112012005583B4 (de) * | 2012-01-06 | 2023-05-17 | Infinity Fuel Cell And Hydrogen Inc. | Elektrochemische Zelle mit verbesserter Wasser- oder Gaswirtschaft |
| EA201591229A1 (ru) | 2013-03-14 | 2016-01-29 | Шир Хьюман Дженетик Терапис, Инк. | Способы очистки матричной рнк |
| LT2970948T (lt) * | 2013-03-15 | 2019-03-25 | Glaxosmithkline Biologicals Sa | Rna gryninimo būdai |
-
2014
- 2014-03-13 LT LTEP14709704.2T patent/LT2970948T/lt unknown
- 2014-03-13 CA CA2906281A patent/CA2906281A1/fr active Pending
- 2014-03-13 HU HUE14709704A patent/HUE042072T2/hu unknown
- 2014-03-13 JP JP2015562160A patent/JP6461830B2/ja active Active
- 2014-03-13 PT PT14709704T patent/PT2970948T/pt unknown
- 2014-03-13 WO PCT/EP2014/055014 patent/WO2014140211A1/fr active Application Filing
- 2014-03-13 BR BR112015023513A patent/BR112015023513A2/pt not_active Application Discontinuation
- 2014-03-13 US US14/775,760 patent/US11155572B2/en active Active
- 2014-03-13 EP EP18212923.9A patent/EP3521429B1/fr active Active
- 2014-03-13 PL PL14709704T patent/PL2970948T3/pl unknown
- 2014-03-13 EP EP14709704.2A patent/EP2970948B1/fr active Active
- 2014-03-13 DK DK14709704.2T patent/DK2970948T3/en active
- 2014-03-13 TR TR2019/03248T patent/TR201903248T4/tr unknown
- 2014-03-13 ES ES18212923T patent/ES2923018T3/es active Active
- 2014-03-13 SI SI201431108T patent/SI2970948T1/sl unknown
- 2014-03-13 ES ES14709704T patent/ES2720200T3/es active Active
- 2014-03-13 CN CN201480015831.4A patent/CN105283548A/zh active Pending
-
2019
- 2019-01-29 HR HRP20190197TT patent/HRP20190197T1/hr unknown
- 2019-03-12 CY CY20191100284T patent/CY1121478T1/el unknown
-
2021
- 2021-01-25 US US17/157,150 patent/US20210214388A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3521429B1 (fr) | 2022-05-04 |
| WO2014140211A1 (fr) | 2014-09-18 |
| EP3521429A1 (fr) | 2019-08-07 |
| ES2720200T3 (es) | 2019-07-18 |
| CA2906281A1 (fr) | 2014-09-18 |
| TR201903248T4 (tr) | 2019-03-21 |
| EP2970948A1 (fr) | 2016-01-20 |
| US20160024139A1 (en) | 2016-01-28 |
| LT2970948T (lt) | 2019-03-25 |
| PL2970948T3 (pl) | 2019-06-28 |
| SI2970948T1 (sl) | 2019-04-30 |
| BR112015023513A2 (pt) | 2017-07-18 |
| HUE042072T2 (hu) | 2019-06-28 |
| US11155572B2 (en) | 2021-10-26 |
| US20210214388A1 (en) | 2021-07-15 |
| ES2923018T3 (es) | 2022-09-22 |
| HRP20190197T1 (hr) | 2019-04-05 |
| CN105283548A (zh) | 2016-01-27 |
| PT2970948T (pt) | 2019-03-20 |
| JP2016512212A (ja) | 2016-04-25 |
| EP2970948B1 (fr) | 2018-12-26 |
| JP6461830B2 (ja) | 2019-01-30 |
| CY1121478T1 (el) | 2020-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210214388A1 (en) | Rna purification methods | |
| JP5129805B2 (ja) | 細胞培養物から精製水疱性口内炎ウイルスを単離するための精製プロセス | |
| EP2361975B1 (fr) | Procédé de purification de virus de la grippe | |
| EP4357355A2 (fr) | Purification de virus | |
| DE202016009003U1 (de) | Zusammensetzung umfassend in vitro transkribierte RNA erhältlich durch ein Verfahren zur Herstellung und Reinigung von RNA mit mindestens einem Schritt mit einer tangentialen Flussfiltration | |
| Tseng et al. | A fast and efficient purification platform for cell-based influenza viruses by flow-through chromatography | |
| AU2013208187B2 (en) | Purification of flaviviruses | |
| EP3581646A1 (fr) | Système chromatographique et de fabrication intégré pour la production de virus | |
| CN106574252B (zh) | 从细胞培养物中纯化脊髓灰质炎病毒的方法 | |
| KR20220029556A (ko) | 전령 rna의 정제 방법 | |
| Steppert et al. | A scalable, integrated downstream process for production of a recombinant measles virus-vectored vaccine | |
| EP3371302B1 (fr) | Procédé de purification de compositions de virus et de telles compositions obtenues | |
| B. Carvalho et al. | Downstream processing for influenza vaccines and candidates: An update | |
| Cui et al. | Comprehensive studies on building a scalable downstream process for mRNAs to enable mRNA therapeutics | |
| TW202214852A (zh) | Rna純化法 | |
| Mundle et al. | Preparation of pure, high titer, pseudoinfectious Flavivirus particles by hollow fiber tangential flow filtration and anion exchange chromatography | |
| US20240043826A1 (en) | Methods for ethanol-free mrna purification | |
| JP5614936B2 (ja) | アニオン交換基が固定された多孔膜を用いた核酸の精製方法 | |
| de Oliveira Vinagre | Get moving enveloped virus manufacturing to the clinic | |
| EP3165604A1 (fr) | Procédé de purification de compositions de virus et de telles compositions obtenues | |
| CN103052399A (zh) | 用于减少病毒组合物中dna杂质的方法 |